New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Hybridoma Sequencing Pitfalls: 3 Top Lessons Learned
MotivationSince the technology's invention in 1975, hybridomas have been a favored method of monoclonal antibody production. By fusing immortal myeloma cells with antibody producing B cells in culture, hybridomas can deliver a nearly infinite supply of antibodies....
Human Antibody Sequencing from Serum
MotivationHuman antibody sequencing is a powerful tool for understanding the humoral immune response. Until recently, B cell-focused approaches have been the only available tool for understanding the diversity and plasticity of the antibody response to challenge (see...
De Novo Antibody Sequencing: Which Enzymes are Best?
De novo antibody sequencing is the process of determining the primary amino acid sequence of an antibody directly from the protein. Determining the sequence of an antibody is a requirement for many downstream activities. Intellectual Property Protection: In order to...
Get In Touch